Unknown

Dataset Information

0

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.


ABSTRACT:

Objective

To study the outcome of patients with multiple sclerosis (MS) and with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and immune reconstitution inflammatory syndrome (IRIS).

Methods

MedWatch reports from Biogen-Idec (manufacturer of natalizumab, Tysabri(®)) were reviewed which comprised all 42 cases of natalizumab-related PML cases since its reintroduction until March 2010.

Results

All except 2 patients with natalizumab-related PML were managed by discontinuation of natalizumab and plasmapheresis/immunoadsorption (PLEX/IA). Seventeen patients had contrast enhancement of PML lesions on neuroimaging at the time of diagnosis before withdrawal/removal of natalizumab (early-PML-IRIS) and 23 patients developed contrast enhancement only after withdrawal/removal of natalizumab (late-PML-IRIS). All patients developed IRIS. IRIS was defined as worsening of neurologic deficits during the immune reconstitution following discontinuation of natalizumab, corroborated by inflammatory changes on neuroimaging. Following PLEX/IA, JC viral load in CSF increased by >10 fold in those with early-PML-IRIS but <2 fold in late-PML-IRIS. IRIS developed earlier and was more severe in early-PML-IRIS (p < 0.05). At the last follow-up, all patients had worse EDSS scores but this was higher in patients with early-PML-IRIS compared to those with late-PML-IRIS (p > 0.05). Mortality was comparable between the 2 groups, 29.4 ± 11% vs 21.7 ± 8.8%. Corticosteroid therapy during IRIS was associated with better Expanded Disability Status Scale outcome, p < 0.05.

Conclusion

Early immunologic rebound in natalizumab-associated PML has worse survival and neurologic outcome. PLEX/IA may accelerate IRIS and its impact on the final outcome is unclear. Corticosteroid therapy provides a modest benefit and needs to be systemically studied in a controlled manner in the management of natalizumab-associated PML-IRIS.

SUBMITTER: Tan IL 

PROVIDER: S-EPMC3174071 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5052063 | biostudies-literature
| S-EPMC6051466 | biostudies-literature
| S-EPMC7951098 | biostudies-literature
2019-01-29 | GSE108649 | GEO
| S-EPMC4334287 | biostudies-literature
| S-EPMC3443811 | biostudies-other
| S-EPMC7305181 | biostudies-literature
| S-EPMC8239348 | biostudies-literature
| S-EPMC4227574 | biostudies-literature